arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Sight Sciences, Inc.

SGHT
$7.49 ▲ +0.40 (+5.64%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
26 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
22
Health
Poor
Bearish
auto_awesome

Analytical Summary

Sight Sciences, Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $404.0M
Dividend Yield
Revenue Growth 12.5%
Op. Margin -63.0%
ROIC -12.9%
FCF / Share $-0.13
Trailing P/E
Price / Book 7.5x
FCF Yield
Debt / Equity 0.86
info Valuation on last close. End-of-day price, Aug 7, 2026.

26-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$19.70M
↑ +12.5%
Net Income Profit after all expenses
$-12.98M
↑ +8.3%
Operating Margin Operating profit as % of sales
-63.0%
↓ -250.1% 5th
FCF / Share Free cash flow per share
$-0.13
↑ +41.9%
Long-Term Debt Long-term obligations
$42.38M
— 0.0%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
5
Returns
14
Financial Health
38
Cash Quality
53

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 7 years · 26 quarters